全文获取类型
收费全文 | 1371798篇 |
免费 | 102842篇 |
国内免费 | 4378篇 |
专业分类
耳鼻咽喉 | 17227篇 |
儿科学 | 44507篇 |
妇产科学 | 36799篇 |
基础医学 | 202381篇 |
口腔科学 | 36302篇 |
临床医学 | 133509篇 |
内科学 | 265428篇 |
皮肤病学 | 26787篇 |
神经病学 | 115460篇 |
特种医学 | 49664篇 |
外国民族医学 | 366篇 |
外科学 | 191018篇 |
综合类 | 29077篇 |
现状与发展 | 2篇 |
一般理论 | 512篇 |
预防医学 | 117376篇 |
眼科学 | 29652篇 |
药学 | 101094篇 |
6篇 | |
中国医学 | 3198篇 |
肿瘤学 | 78653篇 |
出版年
2021年 | 12517篇 |
2019年 | 13005篇 |
2018年 | 17970篇 |
2017年 | 13455篇 |
2016年 | 14375篇 |
2015年 | 16459篇 |
2014年 | 22629篇 |
2013年 | 34246篇 |
2012年 | 47678篇 |
2011年 | 50208篇 |
2010年 | 28849篇 |
2009年 | 26466篇 |
2008年 | 45118篇 |
2007年 | 47591篇 |
2006年 | 47260篇 |
2005年 | 45463篇 |
2004年 | 43177篇 |
2003年 | 40889篇 |
2002年 | 39521篇 |
2001年 | 61002篇 |
2000年 | 62629篇 |
1999年 | 52427篇 |
1998年 | 14790篇 |
1997年 | 13457篇 |
1996年 | 13240篇 |
1995年 | 12559篇 |
1994年 | 11708篇 |
1993年 | 10988篇 |
1992年 | 41625篇 |
1991年 | 40807篇 |
1990年 | 39471篇 |
1989年 | 37379篇 |
1988年 | 34622篇 |
1987年 | 33738篇 |
1986年 | 32186篇 |
1985年 | 30674篇 |
1984年 | 23068篇 |
1983年 | 19625篇 |
1982年 | 11790篇 |
1979年 | 20819篇 |
1978年 | 14828篇 |
1977年 | 12074篇 |
1976年 | 11889篇 |
1975年 | 12125篇 |
1974年 | 14816篇 |
1973年 | 14490篇 |
1972年 | 13369篇 |
1971年 | 12432篇 |
1970年 | 11496篇 |
1969年 | 10415篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
Social phobia, fear of negative evaluation and harm avoidance. 总被引:1,自引:0,他引:1
M Faytout J Tignol J Swendsen D Grabot B Aouizerate J P Lépine 《European psychiatry》2007,22(2):75-79
This naturalistic, prospective investigation examined the role of fear of negative evaluation and the personality trait of harm avoidance in the anxiety levels of treated social phobia patients. One hundred and fifty-seven patients with DSM-IV social phobia were assessed before starting treatment and were then followed for up to two years. As expected, greater fear of negative evaluation and higher scores of harm avoidance were associated with greater anxiety at the 6 month follow-up, and harm avoidance remained a significant predictor at 24 months. However, no evidence was found for an interaction between the personality and cognitive variables examined. The findings are discussed in terms of the relative independence of these factors, as well as their potential implications for the treatment of this disorder. 相似文献
122.
Kelboek H Thuesen L Helqvist S 《世界核心医学期刊文摘》2006,2(5):53-54
目的:SCANDSTENT试验旨在评价西罗莫司洗脱支架(SES)在复杂冠状动脉病变中的应用。背景:与裸金属支架(BMS)相比,在简单冠状动脉病变中使用SES能够改善造影和临.床的结果,但是,有关在复杂病变中使用SES的安全性和有效性的证据有限。方法:322例有症状的复杂冠状动脉疾病患者被随机分配接受SES或BMS治疗。病变形态分别为全闭(36%)、分叉(34%)、开口(22%)或成角(8%)改变。主要终点为支架置入6个月后血管最小管腔直径的差别。 相似文献
123.
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation 总被引:2,自引:0,他引:2
Rolf N. Barth Christina A. Janus Christine A. Lillesand Nancy A. Radke John D. Pirsch Bryan N. Becker Luis A. Fernandez L. Thomas Chin Yolanda T. Becker Jon S. Odorico Anthony M. D''Alessandro Hans W. Sollinger Stuart J. Knechtle 《Transplant international》2006,19(11):885-892
Campath-1H (alemtuzumab) induction was used for renal transplantation in combination with sirolimus as immunosuppression. We previously reported a high (28%) rate of early rejection with this regimen, and now report 3-year outcomes. Twenty-nine patients were recipients of either deceased donor or non-HLA (Human Leukocyte Antigen) identical living donor primary renal allografts. Clinical parameters including infection, malignancy, kidney function, and kidney histology were followed prospectively for 3 years. Three-year cumulative graft and patient survival were 96% and 100%, respectively. Twenty patients were maintained on steroid-free immunosuppressive regimens, and 15 patients were maintained on monotherapy for immunosuppression (12 on sirolimus). No serious infectious complications were observed and two patients developed basal cell skin cancer. The 3-year results of our initial pilot study demonstrate good graft (96%) and patient (100%) outcomes. Campath-1H induction has yielded a high proportion of patients maintained on immunosuppressive monotherapy (57%) without serious infectious- and no malignancy-related complications. The reported regimen yielded novel insights into both Campath-1H and sirolimus therapy in renal transplantation. Because of the higher incidence of early rejection, we recommend a modified strategy of immunosuppression including a brief course of a calcineurin inhibitor. 相似文献
124.
125.
126.
Elderly men with clinical and laboratory evidence of androgen deficiency are eligible for testosterone treatment.
With proper monitoring this is acceptably safe.
In the first year of testosterone treatment there should be a digital rectal examination of the prostate and measurement of prostate specific antigen every three months, thereafter yearly.
The rate of increase of prostate specific antigen (PSA) levels is more significant than its absolute values.
Levels of haemoglobin and the haematocrit should be monitored. 相似文献
127.
Matthew S Lewis Paul Maruff Brendan S Silbert Lis A Evered David A Scott 《Archives of clinical neuropsychology》2006,21(5):421-427
The reliable change index (RCI) expresses change relative to its associated error, and is useful in the identification of post-operative cognitive dysfunction (POCD). This paper examines four common RCIs that each account for error in different ways. Three rules incorporate a constant correction for practice effects and are contrasted with the standard RCI that had no correction for practice. These rules are applied to 160 patients undergoing coronary artery bypass graft (CABG) surgery who completed neuropsychological assessments preoperatively and 1 week post-operatively using error and reliability data from a comparable healthy non-surgical control group. The rules all identify POCD in a similar proportion of patients, but the use of the within subject standard deviation, expressing the effects of random error, as an error estimate is a theoretically appropriate denominator when a constant error correction, removing the effects of systematic error, is deducted from the numerator in a RCI. 相似文献
128.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
129.
130.